The global chemiluminescence immunoassay market is witnessing significant growth owing to the increasing prevalence of chronic and infectious diseases. Chemiluminescence immunoassay (CLIA) is a method used for detecting and quantifying substances, such as peptides, proteins, antibodies, and hormones in biological samples. CLIA uses an antibody tagged with an enzyme to detect the presence of an antigen.

The enzyme helps generate light from specific chemical reactions, which can be measured quantitatively with a Chemiluminescence Immunoassay Market Demand offers various advantages over other conventional methods, including high specificity and sensitivity, reduced time for testing, and minimal use of reagents. Furthermore, CLIA eliminates the need for radioisotopes, making it safe for use in diagnostic labs.

The Global chemiluminescence immunoassay market is estimated to be valued at US$ 10 Billion in 2024 and is expected to exhibit a CAGR of 8% over the forecast period 2024-2029.

Key Takeaways
Key players operating in the chemiluminescence immunoassay market are Siemens Healthineers, Beckman Coulter, Inc., Meso Scale Diagnostics, LLC., F. Hoffmann-La Roche Ltd., Abbott Laboratories, bioMérieux SA, DiaSorin S.p.A.

The increasing adoption of Chemiluminescence Immunoassay Companies by hospitals and diagnostic laboratories presents significant growth opportunities in the market. CLIA analyzers offer superior automation and high-throughput testing capabilities as compared to conventional ELISA kits, making them preferable for high-volume routine testing.

Get More Insights On, Chemiluminescence Immunoassay Market